126 related articles for article (PubMed ID: 12529997)
1. Cytotoxicity of paclitaxel in combination with cisplatin and a new Pt-mercaptopyridine complex.
Ragazzi E; D'Ancona S; Berti E; Carrara M
Anticancer Res; 2002; 22(5):2783-8. PubMed ID: 12529997
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel and radiotherapy: sequence-dependent efficacy--a preclinical model.
Niero A; Emiliani E; Monti G; Pironi F; Turci L; Valenti AM; Marangolo M
Clin Cancer Res; 1999 Aug; 5(8):2213-22. PubMed ID: 10473108
[TBL] [Abstract][Full Text] [Related]
3. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
4. In vitro effect of Pt and Pd mercaptopyridine complexes.
Carrara M; Berti T; D'Ancona S; Cherchi V; Sindellari L
Anticancer Res; 1997; 17(2A):975-80. PubMed ID: 9137437
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
[TBL] [Abstract][Full Text] [Related]
6. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity.
Vadi H; Drewinko B
Cancer Res; 1986 Mar; 46(3):1105-9. PubMed ID: 3080232
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
Untch M; Sevin BU; Perras JP; Angioli R; Untch A; Hightower RD; Koechli O; Averette HE
Gynecol Oncol; 1994 Apr; 53(1):44-9. PubMed ID: 7909786
[TBL] [Abstract][Full Text] [Related]
8. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Bible KC; Kaufmann SH
Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel and N-methylformamide: in vitro interactions in human colon cancer cell line.
Valenti AM; Niero A; Monti G; Marangolo F; Marangolo M
Anticancer Res; 1997; 17(4A):2491-7. PubMed ID: 9252669
[TBL] [Abstract][Full Text] [Related]
11. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
Foroodi F; Duivenvoorden WC; Singh G
Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
[TBL] [Abstract][Full Text] [Related]
12. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells.
Liebmann JE; Fisher J; Teague D; Cook JA
Oncol Res; 1994; 6(1):25-31. PubMed ID: 7919549
[TBL] [Abstract][Full Text] [Related]
13. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines.
Tanaka R; Ariyama H; Qin B; Takii Y; Baba E; Mitsugi K; Harada M; Nakano S
Cancer Chemother Pharmacol; 2005 Jun; 55(6):595-601. PubMed ID: 15731917
[TBL] [Abstract][Full Text] [Related]
14. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
[TBL] [Abstract][Full Text] [Related]
15. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir.
Alexandre J; Nicco C; Chéreau C; Laurent A; Weill B; Goldwasser F; Batteux F
J Natl Cancer Inst; 2006 Feb; 98(4):236-44. PubMed ID: 16478742
[TBL] [Abstract][Full Text] [Related]
16. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
17. In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines.
Tanaka R; Takii Y; Shibata Y; Ariyama H; Qin B; Baba E; Kusaba H; Mitsugi K; Harada M; Nakano S
Cancer Chemother Pharmacol; 2005 Sep; 56(3):279-85. PubMed ID: 15875187
[TBL] [Abstract][Full Text] [Related]
18. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
